SCHEMBL4378463

SCHEMBL4378463

O=c1c(Br)c(Br)ccn1Cc1cccc(F)c1

nearest known ligand 0.64

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 5/20 0.64
POLB P06746 1/20 0.52
THRB P10828 1/20 0.52
ALDH1A1 P00352 3/20 0.48
KDM4E B2RXH2 2/20 0.48
MEN1 O00255 1/20 0.48
PKM P14618 1/20 0.48
KMT2A Q03164 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
PDE1C Q14123 3/20 0.47
DBH P09172 1/20 0.47
PDE1A P54750 1/20 0.46
PDE1B Q01064 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
CYP11B1 P15538 1/20 0.46
CYP11B2 P19099 1/20 0.46
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
GRM2 Q14416 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4384464 0.86 MAPK14 (0.61) MAPK14POLBTHRBALDH1A1KDM4E
SCHEMBL4374173 0.86 MAPK14 (0.61) MAPK14POLBTHRBALDH1A1KDM4E
Hydrochloric Acid SCHEMBL4376344 0.85 MAPK14 (0.60) MAPK14POLBTHRBALDH1A1KDM4E
SCHEMBL4490349 0.82 MAPK14 (0.64) MAPK14POLBTHRBALDH1A1KDM4E
SCHEMBL14547795 0.82 MAPK14 (0.58) MAPK14POLBTHRBALDH1A1KDM4E
SCHEMBL4474073 0.81 MAPK14 (0.57) MAPK14POLBTHRBALDH1A1KDM4E
SCHEMBL4382222 0.81 MAPK14 (0.57) MAPK14POLBTHRBALDH1A1KDM4E
SCHEMBL4392919 0.81 MAPK14 (0.89) MAPK14POLBTHRBALDH1A1KDM4E
SCHEMBL4478413 0.80 MAPK14 (0.56) MAPK14POLBTHRBALDH1A1KDM4E
SCHEMBL6672206 0.79 MAPK14 (0.54) MAPK14POLBTHRBALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7629363-B2 antiinflammatory agent for treating asthma and chronic pulmonary inflammatory disease PFIZER INC (US) 2009-12-08 US disclosed
US-7629363-B2 antiinflammatory agent for treating asthma and chronic pulmonary inflammatory disease PFIZER INC (US) 2009-12-08 US disclosed
US-7629363-B2 antiinflammatory agent for treating asthma and chronic pulmonary inflammatory disease PFIZER INC (US) 2009-12-08 US disclosed
EP-1490064-B1 SUBSTITUTED PYRIDINONES AS MODULATORS OF P38 MAP KINASE PHARMACIA CORP (US) 2009-11-18 EP disclosed
US-7067540-B2 Substituted pyridinones PHARMACIA CORPORATION (US) 2006-06-27 US disclosed
US-20050176775-A1 Substituted pyridinones PHARMACIA CORPORATION 2005-08-11 US disclosed
WO-2005018557-A2 SUBSTITUTED PYRIDINONES PHARMACIA CORPORATION (US) 2005-03-03 WO disclosed
US-20040058964-A1 Substituted pyridinones PHARMACIA LLC 2004-03-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058964-A1 Substituted pyridinones MAPK1, MAPK6, MAPK7 MAPK14 41/4885POLB 1610/4885THRB 1532/4885
US-20050176775-A1 Substituted pyridinones MAPK1, MAPK6, MAP3K6 MAPK14 53/4885POLB 1676/4885THRB 1529/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.